Clinical Trial Update: Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration

View source ↗

Summary

This clinical trial update evaluates the durability of three monthly loading doses of Faricimab in treatment-naïve Neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Faricimab (faricimab)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve | Status: COMPLETED